U.S. FDA Staff Says Covid Vaccine Makers Should Target JN.1, KP.2 Subvariants In 2024-25 Campaign
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA staff has recommended that Covid vaccine makers target the JN.1 and KP.2 subvariants for the 2024-25 vaccination campaign.
June 03, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax (NVAX) may need to adjust its Covid vaccine formulations to target the JN.1 and KP.2 subvariants as recommended by the U.S. FDA staff for the 2024-25 campaign.
The FDA's recommendation will likely prompt Novavax to update its vaccine formulations, which could lead to increased demand and potentially higher revenues if the updated vaccines are effective.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80